Khushnuma Mullanfiroze

Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia

Giorgio Ottaviano, Christos Georgiadis, Soragia Athina Gkazi et al. · Science Translational Medicine · 2022 · 184 citations · Full text

Life Sciences, Biotechnology, Immunology +17

CD19/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL

Sara Ghorashian, Giovanna Lucchini, Kyvi Nguyen et al. · Blood · 2023 · 75 citations · Full text

Life Sciences, Hematology, Immunology +17

CD34<b>+</b>-selected stem cell boost can safely improve cytopenias following CAR T-cell therapy

Khushnuma Mullanfiroze, Arina Lazareva, Jan Chu et al. · Blood Advances · 2022 · 49 citations · Full text

Medicine, Hematology, Immunology +16

T-cell replete cord transplants give superior outcomes in high-risk and relapsed/refractory pediatric myeloid malignancy

Claire Horgan, Khushnuma Mullanfiroze, Archana Rauthan et al. · Blood Advances · 2023 · 43 citations · Full text

Medicine, Hematology, Pediatrics +17

Maintenance therapy for early loss of B-cell aplasia after anti-CD19 CAR T-cell therapy

Maria Gabelli, Macarena Oporto Espuelas, Saskia Burridge et al. · Blood Advances · 2023 · 26 citations · Full text

Life Sciences, Hematology, Immunology +16